Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | ADH1B | P00325 | 1/20 | 0.41 |
| ▸ | ADH1C | P00326 | 1/20 | 0.41 |
| ▸ | ADH1A | P07327 | 1/20 | 0.41 |
| ▸ | ADH7 | P40394 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL446252 | 0.85 | ALDH1A1 (0.45) | ALDH1A1CYP2A6LMNATRPA1ALOX5 | |
| SCHEMBL27752219 | 0.80 | ALDH1A1 (0.48) | ALDH1A1LMNATRPA1MAPK1TSHR | |
| SCHEMBL10831109 | 0.76 | TLR4 (0.51) | ALOX5MAOBHDAC8MAPTSMN1; SMN2 | |
| SCHEMBL8159972 | 0.76 | ALDH1A1 (0.38) | ALDH1A1CYP2A6LMNATRPA1ALOX5 | |
| SCHEMBL27728030 | 0.74 | JUN (0.41) | ALDH1A1LMNAMAPK1HDAC1HDAC6 | |
| SCHEMBL28852837 | 0.74 | ALDH1A1 (0.52) | ALDH1A1CYP2A6LMNATRPA1ALOX5 | |
| SCHEMBL9480701 | 0.74 | ALDH1A1 (0.52) | ALDH1A1CYP2A6LMNATRPA1ALOX5 | |
| SCHEMBL5098432 | 0.71 | — | — | |
| Styrene SCHEMBL14938046 | 0.70 | ALDH1A1 (0.64) | ALDH1A1CYP2A6LMNATRPA1ALOX5 | |
| Benzaldehyde SCHEMBL22400699 | 0.69 | ALDH1A1 (1.00) | ALDH1A1CYP2A6LMNATRPA1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7105559-B2 | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2006-09-12 | — | — | US | claimed |
| US-20050239860-A1 | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION (US) | 2005-10-27 | — | — | US | claimed |
| EP-1482940-A2 | PRODRUGS OF SUBSTITUTED POLYCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2004-12-08 | — | — | EP | claimed |
| EP-1432687-A2 | SUBSTITUTED 5-MEMBERED POLYCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | Pharmacia Corporation (US) | 2004-06-30 | — | — | EP | claimed |
| US-20040082585-A1 | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2004-04-29 | — | — | US | claimed |
| WO-2003093242-A2 | SUBSTITUTED 5-MEMBERED POLYCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2003-11-13 | — | — | WO | claimed |
| US-20030162776-A1 | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade | PHARMACIA CORPORATION | 2003-08-28 | — | — | US | claimed |
| WO-2003028729-A2 | PRODRUGS OF SUBSTITUTED POLYCYCLIC COMPOUNDS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION (US) | 2003-04-10 | — | — | WO | claimed |
| EP-0765873-B1 | Cyclic ureas and analogues useful as retroviral protease inhibitors | DU PONT PHARM CO (US) | 2002-04-17 | — | — | EP | claimed |
| EP-0607334-B1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS | DU PONT MERCK PHARMA (US) | 1997-07-30 | — | — | EP | claimed |
| EP-0765873-A1 | Cyclic ureas and analogues useful as retroviral protease inhibitors | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-04-02 | — | — | EP | claimed |
| EP-0607334-A1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS. | DU PONT MERCK PHARMA (US) | 1994-07-27 | — | — | EP | claimed |
| WO-1994008977-A1 | SUBSTITUTED CAPROLACTAMS AND DERIVATIVES THEREOF USEFUL FOR TREATMENT OF AIDS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-04-28 | — | — | WO | claimed |
| WO-1993007128-A1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-04-15 | — | — | WO | claimed |
| WO-2024071399-A1 | FLUORINE-CONTAINING ETHER COMPOUND, LUBRICANT FOR MAGNETIC RECORDING MEDIUM, AND MAGNETIC RECORDING MEDIUM | 株式会社レゾナック | 2024-04-04 | — | — | WO | disclosed |
| EP-2960233-B1 | NEW THERAPEUTIC AGENTS | CANCER RESEARCH TECH LTD (GB) | 2019-10-30 | — | — | EP | disclosed |
| US-10414726-B2 | Therapeutic agents | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-09-17 | — | — | US | disclosed |
| EP-0607334-A1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS. | DU PONT MERCK PHARMA (US) | 1994-07-27 | — | — | EP | disclosed |
| WO-1994008977-A1 | SUBSTITUTED CAPROLACTAMS AND DERIVATIVES THEREOF USEFUL FOR TREATMENT OF AIDS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-04-28 | — | — | WO | disclosed |
| WO-1993007128-A1 | CYCLIC UREAS AND ANALOGUES USEFUL AS RETROVIRAL PROTEASE INHIBITIORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1993-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162776-A1 | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade | TFPI, F2, SERPINC1 | ALDH1A1 2464/4885CYP2A6 782/4885LMNA 872/4885 |
| US-20050239860-A1 | Substituted 5-membered polycyclic compounds useful for selective inhibition of the coagulation cascade | TFPI, F2, SERPINC1 | ALDH1A1 2464/4885CYP2A6 782/4885LMNA 872/4885 |
| US-10414726-B2 | Therapeutic agents | TP53, MDM2, TP53BP1 | ALDH1A1 2445/4885CYP2A6 3259/4885LMNA 3177/4885 |
| US-20040082585-A1 | Prodrugs of substituted polycyclic compounds useful for selective inhibition of the coagulation cascade | TFPI, F2, PLG | ALDH1A1 2506/4885CYP2A6 776/4885LMNA 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.